Skip to main content
. 2021 Nov 9;16:5–13. doi: 10.1016/j.ejcsup.2021.06.002

Table 1.

Eligible studies.

Trial Patient population Intervention(s) of interest OS data PFS data
ERASMUS GI-NETs and P-NETs [177Lu]Lu-DOTA-TATE IPD IPD
RADIANT-4 GI-NETs Everolimus and BSC Not available Kaplan-Meier
RADIANT-3 P-NETs Everolimus and BSC Kaplan-Meier Kaplan-Meier
NCT00428597 P-NETs Sunitinib and BSC Kaplan-Meier Kaplan-Meier

OS, overall survival; PFS, progression-free survival; IPD, individual patient data; BSC, best supportive care; GI-NETs, gastrointestinal neuroendocrine tumours; P-NETs, pancreatic neuroendocrine tumours.